Erasca/ERAS

$2.55

7.14%
-
1D1W1MYTD1YMAX

About Erasca

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline including 12 disclosed modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. The Company’s pipeline includes five clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, a SHP2 inhibitor, an EGFR inhibitor, and a central nervous system (CNS)-penetrant KRAS G12C inhibitor, and seven discovery-stage programs targeting other key oncogenic drivers. The Company’s lead product candidate is naporafenib, designed to be a reversible, potent and selective ATP-competitive type 2 pan-RAF kinase inhibitor.

Ticker

ERAS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jonathan Lim

Employees

129

Headquarters

San diego, United States

Erasca Metrics

BasicAdvanced
$359.59M
Market cap
-
P/E ratio
-$1.70
EPS
-
Beta
-
Dividend rate

What the Analysts think about Erasca

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
191.37% upside
High $11.00
Low $6.00
$2.55
Current price
$7.43
Average price target

Erasca Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-30.3M
-4.42%
Profit margin
0%
-

Erasca Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.09%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.06
-$0.22
-$0.21
-$0.20
-
Expected
-$0.32
-$0.31
-$0.24
-$0.22
-$0.21
Surprise
231.25%
-29.94%
-11.02%
-9.09%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Erasca stock

Buy or sell Erasca stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing